E. Paietta

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

R. Fisher, C. Coltman, J. Doroshow, 1988, Annals of internal medicine.

Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants.

M. Andreeff, P. Papenhausen, E. Paietta, 1990, Cancer research.

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

Costan, Dietel, R. Warnke, 1996, Cancer research.

HL-T, a new cell line derived from HL-60 promyelocytic leukemia cell cultures expressing terminal transferase and secreting suppressor activity.

P. Papenhausen, E. Paietta, S. Seremetis, 1987, Blood.

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide

A. Zelent, E. Paietta, R. Gallagher, 2004, Leukemia.

Ambiguous Phenotypes In Acute Leukemia.

E. Paietta, E. Paietta, 1990, Leukemia & lymphoma.

Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells.

D. Petrylak, J. Dutcher, E. Paietta, 1991, The American journal of clinical nutrition.

Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia

J. Racevskis, E. Paietta, P. H. Wiernik, 2009, American journal of hematology.